Mylan (NASDAQ:MYL) had its price target hoisted by Mizuho from $45.00 to $51.00 in a report released on Thursday, March 15th, Marketbeat.com reports. Mizuho currently has a buy rating on the stock.
Several other analysts have also weighed in on MYL. Cantor Fitzgerald set a $34.00 price objective on shares of Mylan and gave the stock a hold rating in a report on Thursday, November 30th. ValuEngine raised shares of Mylan from a hold rating to a buy rating in a report on Friday, December 1st. UBS set a $46.00 price target on shares of Mylan and gave the company a buy rating in a report on Monday, December 4th. Guggenheim assumed coverage on shares of Mylan in a report on Tuesday, December 12th. They issued a buy rating and a $59.00 price target for the company. Finally, BidaskClub raised shares of Mylan from a buy rating to a strong-buy rating in a report on Tuesday, December 19th. Nine analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $47.02.
NASDAQ MYL opened at $39.52 on Thursday. The company has a market cap of $20,822.92, a PE ratio of 8.67, a PEG ratio of 1.28 and a beta of 1.34. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.13 and a quick ratio of 0.73. Mylan has a 1-year low of $29.39 and a 1-year high of $47.82.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $1.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.41 by $0.02. The company had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.29 billion. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The company’s revenue was down .9% on a year-over-year basis. During the same quarter last year, the business posted $1.57 earnings per share. equities analysts predict that Mylan will post 5.38 earnings per share for the current year.
In other news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Paul Campbell sold 7,030 shares of Mylan stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total transaction of $309,390.30. Following the transaction, the insider now directly owns 17,054 shares in the company, valued at $750,546.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 344,287 shares of company stock worth $14,409,960. Insiders own 0.69% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Rational Advisors LLC bought a new position in shares of Mylan during the fourth quarter worth $190,000. Advisor Partners LLC bought a new position in shares of Mylan during the fourth quarter worth $214,000. First Personal Financial Services lifted its position in Mylan by 77.1% in the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after acquiring an additional 2,106 shares in the last quarter. M Holdings Securities Inc. bought a new stake in Mylan in the 4th quarter valued at $383,000. Finally, Lombard Odier Asset Management Europe Ltd bought a new stake in Mylan in the 4th quarter valued at $209,000. 84.52% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Mylan (NASDAQ:MYL) Given New $51.00 Price Target at Mizuho” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/mylan-myl-price-target-increased-to-51-00-by-analysts-at-mizuho.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.